Protecting the endothelial glycocalyx in COVID-19
Authors:
Open Access
- 16 May 2024
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 20 (5) , e1012203
Abstract
COVID-19 is a respiratory infection caused by the highly transmissible SARS-CoV-2. While most infected patients exhibit mild to moderate symptoms, a minority may develop severe vascular damage, which can be fatal. One example of this damage is disruption to the endothelial glycocalyx (EG) layer. EG alterations have been implicated in microcirculation changes and severe endothelial dysfunction in COVID-19 [1,2]. Current evidence suggests that host-pathogen interactions, such as hyperimmune activation or persistent presence of viral antigens, are associated with EG damage and may potentially bring about continuous endothelial dysfunction even after clinical recovery. Notably, the glycocalyx is also present on the epithelium, but we will focus on the EG and its implication on vascular health in COVID-19. Additionally, we will propose possible mediators that are linked with EG damage and suggest therapeutic agents that could aid EG restoration and protection.Keywords
Funding Information
- Lee Kong Chian School of Medicine Dean’s Postdoctoral Fellowship
- Lee Kong Chian School of Medicine Early Researcher Network Grant 2023, Nanyang Technological University, Singapore
This publication has 48 references indexed in Scilit:
- Receptor-dependent effects of sphingosine-1-phosphate (S1P) in COVID-19: the black side of the moonMolecular and Cellular Biochemistry, 2023
- Rhamnan sulfate reduces atherosclerotic plaque formation and vascular inflammationBiomaterials, 2022
- Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and SeverityJAMA Network Open, 2022
- Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaquesCell, 2021
- SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2Cell, 2020
- Microvascular dysfunction in COVID-19: the MYSTIC studyAngiogenesis, 2020
- The Glycocalyx and Its Role in Vascular Physiology and Vascular Related DiseasesCardiovascular Engineering and Technology, 2020
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2Cell, 2020
- Nitric Oxide and Endothelial DysfunctionCritical Care Clinics, 2020
- Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitusDiabetologia, 2010